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The transcriptional repressor HDAC7 promotes
apoptosis and c-Myc downregulation in particular types
of leukemia and lymphoma
B Barneda-Zahonero1, O Collazo1,11, A Azagra1,11, I Fernández-Duran1, J Serra-Musach2, ABMMK Islam3, N Vega-García4, R Malatesta4,
M Camós4, A Gómez5, L Román-González1, A Vidal6, N López-Bigas7,8, A Villanueva9, M Esteller5,8,10 and M Parra*,1
The generation of B cells is a complex process requiring several cellular transitions, including cell commitment and differentiation.
Proper transcriptional control to establish the genetic programs characteristic of each cellular stage is essential for the correct
development of B lymphocytes. Deregulation of these particular transcriptional programs may result in a block in B-cell
maturation, contributing to the development of hematological malignancies such as leukemia and lymphoma. However, very little
is currently known about the role of transcriptional repressors in normal and aberrant B lymphopoiesis. Here we report that
histone deacetylase 7 (HDAC7) is underexpressed in pro-B acute lymphoblastic leukemia (pro-B-ALL) and Burkitt lymphoma.
Ectopic expression of HDAC7 induces apoptosis, leads to the downregulation of c-Myc and inhibits the oncogenic potential of
cells in vivo, in a xenograft model. Most significantly, we have observed low levels of HDAC7 expression in B-ALL patient samples,
which is correlated with the increased levels of c-Myc. From a mechanistic angle, we show that ectopically expressed HDAC7
localizes to the nucleus and interacts with the transcription factor myocyte enhancer factor C (MEF2C) and the corepressors
HDAC3 and SMRT. Accordingly, both the HDAC7–MEF2C interaction domain as well as its catalytic domain are involved in the
reduced cell viability induced by HDAC7. We conclude that HDAC7 has a potent anti-oncogenic effect on specific B-cell
malignancies, indicating that its deregulation may contribute to the pathogenesis of the disease.
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Proper generation of mature B lymphocytes is the result of
complex cell lineage commitment and differentiation pro-
cesses. Each cellular transition is tightly regulated at the
transcriptional level by the action of linage-specific transcrip-
tion factors (TFs), such as PU.1, Ikaros, myocyte enhancer
factor C (MEF2C), E2A and PAX5 among others.1–9 The
deregulation of these particular transcriptional programs may
result in a block in the differentiation and a hyperproliferative
cellular state, thereby contributing to the development of
hematological malignancies such as leukemia and lymphoma.
Aberrant expression or mutation of many of the lineage-
specific TFs involved in B lymphocyte development have been
linked to the outcome of hematopoietic malignancies.10,11 In
addition, the overexpression of c-Myc has been found in T-cell
acute lymphoblastic leukemia (T-ALL) and B-ALL, and some
types of B-cell lymphoma, such as Burkitt lymphoma, present
translocations in the MYC gene (c-MYC-IgH).12 The dereg-
ulation of B-cell TFs in combination with chromosomal
aberrations, such as gene translocations (ETV6-RUNX1 and
BCR-ABL1) and rearrangements in the MLL gene are key
events in aberrant B lymphopoiesis and considered as primary
lesions.11,13
In recent years, the idea has begun to emerge that, in
addition to the activation of gene expression, transcriptional
repression is a fundamental mechanism to ensure proper B
lymphopoiesis.3,14,15 Among the different types of transcrip-
tional repressors, histone deacetylases (HDACs) are thought
to be crucial enzymes in many physiological and pathological
processes.16,17 Mutation and/or aberrant expression of
HDACs have often been observed in human disease, in
particular cancer, making them important therapeutic
targets.18,19 In pathological situations where classic HDACs
are overexpressed, HDAC inhibitors (HDIs) have emerged as
promising therapeutic agents.19 However, it is worth mention-
ing that the contribution of HDACs to cancer could be due to
mechanisms other than overexpression. In fact, HDACs may
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also present truncating or inactivating mutations.18 Therefore,
we are far from fully understanding the contribution of
individual HDACs to cancer.
Of the various HDACs, HDAC7 appears to be a lymphoid-
specific transcriptional repressor.20–26 In addition to its critical
role in T lymphocyte biology, we have recently reported that
HDAC7 is critical in maintaining the genetic identity of B
lymphocytes.20 Interestingly, HDAC7 has been identified as a
target gene in hematopoietic cancers in a PiggyBac transpo-
son mutagenesis screening in mice.27 On the basis of our
recent findings, we postulated that HDAC7 might be deregu-
lated in B-cell malignancies. Here we report the loss of HDAC7
expression in cell lines established from B-ALL and Burkitt
lymphoma as well as in pro-B-ALL samples from patients.
Forced expression of HDAC7 induces the apoptosis of the
cells. Strikingly, the presence of HDAC7 results in the
downregulation of the oncogene c-Myc. HDAC7 expression
interferes with the oncogenic potential of the cells in a
xenograft model. Most significantly, we have found low levels
of HDAC7 expression in B-ALL samples from patients, which
are associated with high levels of c-Myc. Taken together, our
findings suggest that HDAC7 expression may exert an anti-
oncogenic activity in particular types of B-cell malignancies
and that its deregulation may contribute to the pathogenesis of
B-ALL and B-cell lymphoma.
Results
HDAC7 is underexpressed in pro-B-ALL and B-cell
lymphoma. First, to further validate the notion that HDAC7
is a lymphoid-specific transcriptional repressor within the
hematopoietic system we examined the Immunological
Genome Project Database (Immgen) (http://www.immgen.
org/). Using this database we confirmed that HDAC7 is
specifically expressed in lymphoid cells but not in cells from
the myeloid lineage (Supplementary Figure 1). This finding
led us to speculate that HDAC7 expression could be
deregulated in B-cell malignancies. To test this hypothesis,
we first examined HDAC7 expression levels in a publicly
available microarray GEO data set (GSE34861), which
consists of the gene expression profile of 191 samples of
adult B-ALL and 3 normal samples. The B-ALL samples
comprised 28 corresponding to pro-B-ALL, 125 to early pre-
B-ALL, 23 to pre-B-ALL, 5 to mature B-ALL, 5 to CD56+
B-ALL and 5 to transitional-pre-B-ALL immunophenotypes.
Analysis using the Fisher test showed that HDAC7 was
significantly associated with underexpression in pro-B-ALL
samples (Figure 1a). We found no significant association with
deregulation of HDAC7 expression in samples from the other
immunophenotypes analyzed (Figure 1a). To further confirm
our findings, we next assessed the HDAC7 protein levels in
established cell lines from six B-ALLs. We observed that
SD-1 and JVM-2 cells presented low or undetectable HDAC7
protein levels (Figure 1b). Next we tested whether HDAC7
expression could also be deregulated in lymphomas. We
found that HDAC7 was underexpressed in the Burkitt
lymphoma-derived Namalwa cell line (Figure 1c). Altogether,
these data indicate that HDAC7 is deregulated in particular
types of B-ALL and B-cell lymphoma.
HDAC7 expression induces apoptosis in SD-1 and
Namalwa cells. To assess whether the absence of HDAC7
is associated with the oncogenic features of SD-1 and
Namalwa cells we adopted a gain-of-function experimental
approach. We generated a doxycycline-inducible system
to express HDAC7 exogenously in both the cell lines
(Figures 2a and b). Expression of HDAC7 after the addition
of doxycycline to SD-1 cells resulted in complete cell growth
arrest over a course of 3 days (Figure 2c). In contrast,
addition of doxycycline to the parental SD-1 cell line had no
significant effect on cell growth, demonstrating that HDAC7
specifically mediates the growth arrest of the cells
(Figure 2c). We then tested whether the reduction in the
total number of cells was the result of a block in cell
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Figure 1 HDAC7 is underexpressed in pro-B acute lymphoblastic leukemia (ALL) and B-cell lymphoma. (a) Table shows the results of the Fisher test. The q-values result
from multiple correction by FDR. The OR (odds ratio) shows the association between an ALL type and HDAC7 underexpression. OR41 indicates that ALL type is positively
associated with underexpression, whereas ORo1 indicates that it is negatively associated with underexpression. An OR= 1 indicates no association between ALL type and
regulation. (b) and (c) represent the western blots for HDAC7 in B-ALL and lymphoma cell lines
HDAC7: a new target in leukemia and lymphoma
B Barneda-Zahonero et al
2
Cell Death and Disease
proliferation by performing an MTT assay in the absence
and presence of HDAC7. HDAC7 expression significantly
reduced the cell viability of both SD-1 and Namalwa cell lines
(Figures 2d and e). To rule out the possibility that the effect
observed on cell viability is due to the toxicity of ectopic
overexpression of HDAC7, we generated HDAC7-inducible
lines in cells that express normal HDAC7 levels. We found
that ectopic expression of HDAC7 in RAJI and TOM-1 cell
lines did not affect their viability (Supplementary Figure 2a
and b). Moreover, the class IIa HDACs, HDAC4 and HDAC9
were found to be expressed in both SD-1 and Namalwa cells
in the absence and in the presence of doxycycline indicating
that the effect observed was specific to the expression of
HDAC7 (Supplementary Figure 2c). Next we examined
whether HDAC7 could induce apoptosis and assessed the
cell cycle status. We observed a significant accumulation of
cells in subG0 at 48 and 72 h after doxycycline treatment of
both SD-1 and Namalwa cell lines, demonstrating that
HDAC7 induced apoptosis (Figures 2d and e and
Supplementary Figure 3). These findings indicate that the
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Figure 2 Forced expression of HDAC7 in SD-1 and Namalwa cell lines blocks their proliferation capacity and induces apoptosis. (a) and (b) SD-1 and Namalwa cells were
transduced to express HDAC7 in a doxycycline-inducible manner (SD-1-Tet-On-Tight-HDAC7 and Namalwa-Tet-On-Tight-HDAC7 cells). Representative western blots showing
HDAC7 protein levels after cell treatment with doxycycline. (c) SD-1-Tet-On and SD-1-Tet-On-Tight-HDAC7 cells were cultured and treated, or not, with doxycycline. At the
indicated times after treatment, the cell number was assessed by cell counting. Trypan blue-dyed cells were omitted from the cell counts. Means± S.D. of the four independent
experiments performed in triplicate. (d) and (e) Mean± S.E.M. of the absorbance units from five independent MTTassays performed in triplicate, of SD-1-Tet-On-Tight-HDAC7
(left) and Namalwa-Tet-On-Tight-HDAC7 (right) treated, or not, with doxycycline. ***Po0.001; ****Po0.0001. (f) and (g) show the percentage of cells in SubG0 from three
independent experiments in SD-1-Tet-On-Tight-HDAC7 (left) and Namalwa-Tet-On-Tight-HDAC7 (right) cells treated, or not, with doxycycline for the indicated times. *Po0.05;
**Po0.01; ***Po0.001
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absence of HDAC7 could be associated with the survival of
both the cancer cell lines and suggest that its re-expression
may exert a therapeutic anti-oncogenic effect.
HDAC7 expression induces apoptosis and inhibits tumor
growth in a xenograft model. To determine the physiolo-
gical consequences of HDAC7 expression in SD-1 and
Namalwa cells we performed in vivo functional experiments
using a xenograft model in athymic mice. First, SD-1 cells
were injected subcutaneously into the back of several
athymic mice. When tumors reached a homogeneous size
they were randomly allocated into two treatment groups: (i)
mice drank glucose; and (ii) drank glucose plus doxycycline
in water. Tumors in mice taking glucose-treated water that did
not express HDAC7 continued to grow. Strikingly, tumors in
mice treated with doxycycline showed a marked decrease in
their size (Figures 3a and b). Next to test the effect of HDAC7
expression on the lymphomagenic capacity of the Namalwa
cell line, 1.5 × 106 cells were injected orthotopically into the
spleen of 19 athymic mice and they were randomly allocated
into two treatment groups. (i) mice drank glucose; and (ii)
drank glucose plus doxycycline in water. Notably, 15 days
later, the tumors of mice treated with doxycycline were almost
undetectable at palpation. At that point, all mice were killed
and their spleens surgically removed. Similar to the results
obtained with leukemic cells, the expression of HDAC7 in
Namalwa cells markedly interfered with the growth of
lymphomas (Figures 3c and d). Immunofluorescence assays
revealed a significant reduction of proliferation, as revealed
by Ki67 staining, and increased apoptosis in tumor cells
expressing HDAC7 (Figures 3e and f and Supplementary
Figure 4). Thus, our in vivo data confirm that HDAC7 induces
apoptosis and exerts a potent anti-oncogenic effect suggest-
ing that its absence may be involved in the pathogenesis of
specific types of B-ALL and B-cell lymphoma.
HDAC7 expression induces the apoptotic gene program
of leukemic cells. As HDAC7 is a transcriptional regulator,
we decided to investigate the impact of HDAC7 expression
on the global gene expression profile of SD-1 cells.
Microarray analysis revealed that 660 genes were differen-
tially expressed when HDAC7 was ectopically expressed
in SD-1 cells. Of these, 410 genes were upregulated
and 250 were downregulated (Supplementary Figure 5,
Supplementary Data Sets 1 and 2). Next we examined the
list of upregulated genes after HDAC7 expression and looked
for the presence of apoptosis-related genes. We observed
that HDAC7 induced the expression of several genes, such
as CD44, FAS, ATM, TP53BP2, CD40 and BIRC3, with
known apoptotic functions (Supplementary Table 1). In
addition, we also found that the presence of HDAC7 led to
the upregulation of genes related to immune processes (IL16,
FCGR2A, IRAK2, CD86 and CD40, among others) and
cancer (RASSF4, RAB31, NEDD9 and RASSF2, among
others; Supplementary Table 1). To further investigate if
HDAC7 expression leads to the activation of the apoptotic
genetic program in SD-1 cells, we performed a gene set
enrichment analysis based on the gene ontology (GO)
categories corresponding to the biological processes and
on the KEGG pathways. The biological processes analysis
revealed that the set of genes upregulated upon HDAC7
expression belong to GO categories representing immune
system processes, regulation of cell death and regulation of
cell proliferation, among others (Figure 4a). KEGG pathway
enrichment analysis confirmed that the genes whose
expression was induced by HDAC7 were significantly
enriched in the apoptosis pathway (Figure 4b). A selected
number of genes were validated by RT-qPCR (Figure 4c). To
better understand the mechanism associated with the
HDAC7-induced apoptotic pathway in SD-1 cells, we
investigated the possible enrichment of TF motifs from the
TRANSFAC database in the set of upregulated genes. We
observed a significant enrichment of a set of TFs. Remark-
ably, we found the enrichment of the binding motif for p53,
suggesting that the induction of apoptosis may occur in a
p53-mediated manner (Figure 4d). To test this possibility we
assessed the status of p53 activation after the expression of
HDAC7 in both SD-1 and Namalwa cells and found that the
presence of HDAC7 in both the cell lines resulted in the
phosphorylation and acetylation of p53 at serine 392 and
lysine 382, respectively, two post-translational modifications
indicative of p53 activation (Figure 4e). Overall, our data
demonstrate that HDAC7 induces apoptosis presumably via
the activation of the p53 pathway.
HDAC7 represses the expression of c-Myc. Our findings
strongly indicate that HDAC7 exerts a strong anti-oncogenic
effect in pro-B-ALL and B-cell lymphoma. Given that HDAC7
is a transcriptional repressor, we wondered whether its
expression could lead to the repression of key oncogenes
in leukemia and lymphoma. We examined our microarray
data and looked for the presence of potential oncogenes in
the list of downregulated genes after HDAC7 expression.
Strikingly, we observed that the presence of HDAC7 resulted
in the downregulation of crucial genes with known oncogenic
potential, such as MYC, TERT and AICDA (Supplementary
Table 2). This finding was validated by RT-qPCR in both SD-1
and Namalwa cells (Figures 5a and b). Using the TRANSFAC
database, we found a significant enrichment of the binding
site motifs for MYC factors in the HDAC7-induced down-
regulated genes (Figure 5c). Moreover, we also found that
HDAC7 expression resulted in the reduction of c-Myc protein
levels (Figure 5d). Next we tested whether the ectopic
expression of c-Myc could prevent the cell growth arrest
induced by HDAC7 in both SD-1 and Namalwa cells. We
found that exogenous expression of c-Myc induced a
significant rescue of cell growth in cells treated with
doxycycline to express HDAC7. This finding further corrobo-
rates that the anti-oncogenic capacity of HDAC7 is mediated,
at least in part, by the downregulation of c-Myc in SD-1 and
Namalwa cells (Figure 5e). To confirm the relevance of our
finding we further analyzed the published microarray GEO
data set (GSE34861) and examined whether there was an
association between HDAC7 and c-Myc expression levels.
Strikingly, we found that a low level of expression of HDAC7
was significantly associated with high levels of c-Myc in
B-ALL patients (Figure 5f). These data strongly support the
hypothesis that HDAC7 posses an anti-oncogenic potential
on the B-cell malignancies studied.
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HDAC7 interacts with MEF2C, HDAC3 and SMRT and is
localized in the nucleus. Class IIa HDACs posses a highly
conserved C-terminal catalytic domain that mediates their
recruitment to a corepressor complex containing HDAC3 and
SRMT/N-CoR. In addition, class IIa HDACs contain a long
N-terminal region that has been shown to mediate their
interaction with tissue-specific TFs and their phosphorylation-
dependent subcellular localization. To gain an insight into
the mechanism of action of HDAC7, we first assessed its
subcellular distribution in Namalwa cells treated, or not,
with doxycycline. As expected, we found that ectopically
expressed HDAC7 was mainly localized in the nuclear
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compartment (Figure 6a). Next we tested the potential
requirement of both the TF-binding domain and the catalytic
domain in HDAC7-decreased cell viability. We generated
retroviral vectors carrying a C-terminal truncated construct
HDAC7 (1–487) that completely lacks the HDAC catalytic
domain but contains the MEF2 interacting motif, and an
N-terminal truncated construct HDAC7 (438–915) bearing the
enzymatic motif but lacking the MEF2 domain. Expression of
wild-type HDAC7 resulted in a significant decrease in the
viability of Namalwa cells, whereas the expression of HDAC7
(1–487) and HDAC7 (438–915) constructs did not have a
significant effect (Figure 6b). We have recently reported that
HDAC7 interacts with the TF MEF2C in B lymphocytes. To
address whether ectopically expressed HDAC7 specifically
interacts with MEF2C in Namalwa cells, we performed co-
immunoprecipitation experiments. We found that HDAC7
associated with MEF2C and not with other B-cell-specific TFs
in Namalwa cells (Figure 6c). We also observed that HDAC7
interacted with HDAC3 and SMRT (Figure 6c). It has been
proposed that HDAC7 lacks any enzymatic activity and that it
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exerts its repressive function via the interaction with
HDAC3. However, the function of HDAC7 in the absence of
HDAC3 has not been properly studied. To address whether
HDAC7 induces cell growth arrest through the interaction
with HDAC3 in SD-1 and Namalwa cells, we performed
a loss-of-function experimental approach (Figure 6d).
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Strikingly, we observed that HDAC3 knockdown in both cell
lines reduced cell growth in the absence of HDAC7, indicating
that targeting HDAC3 would also have an anti-oncogenic
effect. However, in the presence of HDAC7, lowering HDAC3
levels did not lead to a rescue in the cell growth block induced
by HDAC7 (Figure 6e). This result indicates that HDAC7 may
possess an intrinsic enzymatic activity independent of
HDAC3. Next we wondered whether the expression of
HDAC7 partners could be deregulated in leukemia and
lymphoma cells expressing HDAC7. To test this possibility,
we determined the protein levels of HDAC3, MEF2C and
c-Myc in leukemia and lymphoma cell lines. As expected,
most of the cell lines express high levels of c-Myc (Figure 6f).
However, we did not observed differences in the expression
of HDAC3 between the cell lines tested (Figure 6f). This
supports the finding that HDAC7 exerts its anti-oncogenic
effect in an HDAC3-independent manner. Strikingly, we
observed that in contrast to SD-1 and Namalwa cells that
express the TF MEF2C, many of the other cell lines either
lack or express very low levels of this TF. Therefore, the
absence of MEF2C may explain why those cell lines can
tolerate normal HDAC7 levels. Altogether, these experiments
demonstrate that both the HDAC7–MEF2C interaction and its
catalytic domain, are necessary for HDAC7 to reduce the
viability of SD-1 and Namalwa cells.
Discussion
We present data demonstrating that the transcriptional
repressor HDAC7 has a potent anti-oncogenic effect in
particular types of B-ALL and B-cell lymphoma. First, we
report the loss of HDAC7 expression in pro-B-ALL patients
and in established B-ALL and B lymphoma cell lines. Second,
we show that HDAC7 expression induces apoptosis and
inhibits the oncogenic potential of the cell lines tested in vitro
and in vivo. Third, using genome-wide transcriptome profiling
we show that ectopically expressed HDAC7 induces the
expression of apoptotic genes and leads to the downregula-
tion of key oncogenes such as c-Myc. And fourth, we report
the key finding that samples from pro-B-ALL patients present
low levels of HDAC7, which are associated with high levels of
c-Myc expression.
The idea that HDACs are aberrantly overexpressed in
cancer has been prevalent for some time, to the point where it
is stated as dogma. In fact, inhibition of HDACs has been
reported to have promising effects in cancer treatment.18
However, most HDIs are disadvantaged by their lack of
enzyme specificity and have a broad range of potential side
effects.28 Our findings from this study reveal an unexpected
anti-oncogenic function for an HDAC in pro-B-ALL and B-cell
lymphoma. We demonstrated that the expression of
a crucial HDAC, HDAC7, for B lymphocyte biology is lost in
pro-B-ALL patients and in the B-ALL and B-cell lymphoma cell
lines, and that its re-expression has a potent anti-oncogenic
effect. In this regard, it is important to note that under-
expression levels, truncating or inactivating mutations in some
HDACs in cancer have also been reported.18 Recently,
Heideman et al.29 demonstrated that the reduction in HDAC1
and HDAC2 expression levels in vivo brings about T-cell
lymphomagenesis owing to a block in the early thymocyte
development. A different study demonstrated that the lack of
HDAC3 specifically in the liver leads to the development of
hepatocellular carcinomas.30 Therefore, our understanding of
the contribution of specific HDACs to a given cancer type
continues to be incomplete. Efforts are needed to establish
definitively the role of specific HDACs and whether they are
overexpressed, underexpressed or mutated in a particular
cancer. This will allow for the design and development of
HDAC isoform-specific HDIs or other molecules that can
modulate the expression of a particular HDAC.
Several reports have described a potential role for HDAC7 in
hematological malignancies.27,31–34 However, the functional
contribution of HDAC7 to B-ALL remains to be elucidated. In
an elegant study using a PiggyBac transposon screening
in mice, Rad et al.27 revealed that HDAC7 is a target gene in
hematopoietic cancers. In addition, HDAC7 has been shown
to be overexpressed in childhood ALL.34 This discrepancy with
our data could be explained by the different analytical methods
used in the two studies. Tone and colleagues analyzed
94 samples from childhood ALL patients, of which 78
corresponded to B-ALL and only 4 had a pro-B-ALL
immunophenotype.34 In the present work, we took advantage
of a data set obtained in an integrative epigenomic study
where they analyzed adult B-ALL patients distinguishing
different immunophenotypes.35 Performing an accurate ana-
lysis of the expression of HDAC7, we found that HDAC7 was
significantly underexpressed in pro-B-ALL patients. Therefore,
it is possible that Gonzaga and colleagues did not find low
levels of HDAC7 because pro-B-ALL was underrepresented in
their study.
Why is HDAC7 underexpressed in specific types of B-ALL
and B-cell lymphoma? Leukemogenesis and lymphomagen-
esis are complex malignant processes that may comprise a
broad number of driver mutations, rearrangements and
translocations in crucial genes, which are considered as
primary lesions. We speculate that the loss of HDAC7
expression in particular types of leukemia and lymphoma
may be the result of the transcriptome changes induced by a
specific primary lesion. Several mechanisms could account for
the loss of HDAC7 expression in leukemia and lymphoma.
First, it is possible that the HDAC7 gene suffers from DNA
methylation leading to its epigenetic silencing. A second
potential mechanism responsible for the deregulation of
HDAC7 is the action of microRNAs. In fact, another class IIa
HDAC, HDAC4, has been reported to be a target of miR-155 in
a Eu-miR-155 transgenic mouse model.36 Eu-miR-155 mice
exhibit high proliferation rates of pre-B cells and develop
lymphoma/leukemia. Croce and colleagues have shown that
miR-155 targets HDAC4, leading to its underexpression, and
that the ectopic expression of HDAC4 in diffuse large B-cell
lymphoma cells inhibits miR-155-induced proliferation and
increases the apoptosis of the cells.36 The elucidation of the
molecular mechanisms involved in the repression of HDAC7 in
pro-B-ALL and B-cell lymphoma is a current focus of study
in our laboratory. The modulation of HDAC7 expression in
specific types of B-ALL and B-cell lymphoma leading to the
induction of apoptosis and the downregulation of the c-Myc
oncogene may be a promising therapeutic pathway in future.
On the basis of this study, HDAC7 appears to be a promising
therapeutic target in these particular types of hematological
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disease. Our datawill help to generate new, highly specific and
personalized therapies for the treatment of pro-B-ALL and
B-cell lymphoma.
Materials and methods
Plasmids and retroviral supernatant generation. pRetro-X-Tight-Pur-
HDAC7 constructs were generated by cloning full length or deleted HDAC7 cDNAs
obtained by EcoRI digestion of the pcDNA3.1-HDAC7 plasmids into the pRetro-X-
Tight-Pur vector (Takara Bio, Otsu, Japan). MSCV-c-Myc-GFP retroviral vector was
obtained from Addgene (Cambridge, MA, USA). pLKO.1-shHDAC3KD1-GFP and
pLKO.1-shHDAC3KD2-GFP constructs were generated by cloning two validated
shRNAs sequences that target HDAC3 (SIGMA, St. Louis, MO, USA), into the
pLKO.1-GFP lentiviral vector. For retrovirus generation, pRetro-X-Tight-Pur-HDAC7
and pRetro-X-Tet-On-Advanced (Takara Bio) plasmids were transfected into the
packaged cell line Platinum-E and the supernatant was collected 48 h post
transfection. For lentivirus generation, the generated constructs were transfected
into 293 T cells together with enveloped and packaging plasmids and supernatant
was collected 48 h post transfection.
Retroviral transduction and doxycycline treatment. Inducible
HDAC7 expression in SD-1 and Namalwa cell lines was achieved by the generation
of the SD-1 and Namalwa Tet-On-Tight-HDAC7 cell lines. In brief, SD-1 and
Namalwa cells were first infected with the supernatant containing the pRetro-X-Tet-
On-Advanced viral particles overnight and 72 h later selected with 1.5 μg/ml
geneticin (GIBCO, Carlsbad, CA, USA). Next the selected cells were infected with
the pRetro-X-Tight-Pur-HDAC7 viral particles overnight and after 72 h selected with
3 μg/ml puromycin. For HDAC7 expression, cells were treated with 500 ng/ml of
doxycycline for the indicated periods. For c-Myc expression or HDAC3 knockdown,
SD-1 and Namalwa Tet-On-Tight-HDAC7 cell lines were transduced with MSCV-
Empty-GFP, MSCV-c-Myc-GFP, pLKO.1-GFP and pLKO.1-shHDAC3KD1+KD2-GFP
and GFP-positive cells were sorted by flow cytometry.
Proliferation and cell cycle assays. For the MTT assays, 5 × 104 cells
were plated onto 24-well plates. At different times, MTT was added at a final
concentration of 5 mg/ml. After incubation for 3 h (37 °C, 5% CO2), the blue
formazan derivative was solubilized in dimethyl sulfoxide and the absorbance was
measured at 570 nm. Cell proliferation was also assessed by cell counting. Cell
cycle and apoptosis were assessed by propidium iodide staining (distribution of cells
in G0/G1, S and G2/M phase, and in SudG0) followed by flow cytometry analysis
using a Gallios flow cytometer (Gallios, Beckman-Coulter, Brea, CA, USA).
Co-Immunoprecipitation assays. Co-immunoprecipitation assays were
performed as previously described in.26
Mouse xenograft assay. Five-week-old male athymic nu/nu mice (Charles
River, Wilmington, MA, USA), housed under specific pathogen-free conditions, were
used in this study. To minimize tumor growth dispersion observed by subcutaneous
injection of SD-1 cell line, SD-1-Tet-On-Tight-HDAC7 cells were developed in two
steps: (i) 5 × 106 SD-1-Tet-On-Tight-HDAC7 cells were subcutaneously injected into
the back of n= 5 animals. Once the tumors grew, they were harvested, cut into
equal size small fragments and subcutaneous transplanted into the back of other
nude mice. Mice bearing subcutaneous engrafted tumors (150–200 mm3) were
randomly allocated in the two treatment groups: (i) mice drank 1% glucose; and (ii)
drank 1% glucose plus 2 mg/ml doxycycline in water. The tumor growth was
recorded twice per week and tumor volume (in mm3) was estimated according to
the formula V= π/6 × L ×W2.(W) width and (L) length. For Namalwa-Tet-On-Tight-
HDAC7 cells (1.5 × 106) were injected orthotopically into the middle of the spleen
and the tumors were monitored by palpation twice a week. Likewise, mice were
randomly allocated in the two treatment groups: (i) mice drank 1% glucose; and (ii)
drank 1% glucose plus 2 mg/ml doxycycline in water. At the time of killing (30 days
after induction in SD-1 cells and 15 days for Namalwa cells) all the tumors were
excised and weighed, analyzed macroscopically and by hematoxylin and eosin
tissue staining for histological assessment. All experiments were approved by the
IDIBELL animal care and use committee.
Immunofluorescence. Tumors were fixed in 4% formaldehyde overnight at
4 °C, embedded in paraffin wax and sectioned at 4 μm. For immunofluorescence staining,
antigen retrieval was performed in 10mM sodium citrate (pH 6.0). Tumor sections were
blocked with 5% horse serum in phosphate-buffered saline for 1 h at room temperature
and incubated with primary antibodies overnight at 4 °C. The primary antibody used
was anti-Ki67 (Thermo Scientific, Alcobendas, Spain). Tumor sections were then
incubated with secondary antibodies for 1 h at room temperature. Nuclei were
stained using 4′,6-diamidino-2-phenylindole. Samples were imaged on a Leica TCS
SP5 spectral confocal microscope (LEICA, Barcelona, Spain), with a 63XNA 1.4
objective and using the LASAF software version 7 (LEICA). Microphotographs were
analyzed with Fiji software (http://fiji.sc/). In brief, images were analyzed in gray
scale and median filtered. More than 2400 cells per animal (three glucose; three
glucose+Doxy) where analyzed in Ki67 staining and apoptotic nuclei.
Western blot. Western blot analysis was performed according to standard
procedures. Western blots were developed with the ECL detection kit (Amersham
Biosciences, Pittsburgh, PA, USA).
RT-qPCR expression analyses. RT-qPCR analysis were performed as
previously described in.20
GSE34861 analysis. Expression profiling (microarray) of 191 samples of adult
B-lineage ALL and 3 normal pre-B samples were extracted from GEO database
(GSE34861). Raw data were robust multichip average (RMA) normalized using the
RMA algorithm in NimbleScan 2.5 software (Roche NimbleGen, Inc, Basel,
Switzerland). For differential expression analysis, average Log2 expression of the
normal samples were subtracted from each cancer patient expression data (Log2
value) for each gene using in house python script. The association between the
immunophenotypes of the various B-ALL patients and the downregulated levels of
HDAC7 was examined using the Fisher test. Two HDAC7 probes were analyzed:
cds1 Homo sapiens histone deacetylase 7A (HDAC7A), transcript variant 1, mR and
cds2 Homo sapiens histone deacetylase 7A, mRNA (cDNA_clone_MGC:74915_
IMAGE:6179239), complete cds. Both the probes were normalized with respect to
values of healthy patients. GSE34861 data were analyzed under R statistical
language. The q-values where obtained from multiple correction by false discovery
rate (FDR). The odds ratio (OR) shows the association between ALL
immunophenotype and the downregulation of HDAC7. If an OR41 indicates that
ALL immunophenotype is positively associated with having downregulated levels of
HAC7, whereas ORo1 indicates negative association between having the specific
ALL immunophenotype and HDAC7 downregulation. An OR= 1 indicates no
association between ALL immunophenotype and HDAC7 expression. To identify the
associations between the characterized cytogenetic features of B-ALL and low
levels of HDAC7 expression we applied the Wilcox test. Data were analyzed using
the R statistical language. To assess the correlation between c-MYC and the two
HDAC7 probes in the 191 B-ALL patients the Pearson correlation coefficient was
computed (rho) and linear regression was performed.
Microarray experiments. SD-1 Tet-On-Tight-HDAC7 or SD-1 cells were
treated or not for 24 h with doxycycline and collected in Trizol reagent (Invitrogen,
Carlsbad, CA, USA). RNA was extracted as described above. PCR-amplified RNAs
were hybridized against an Affymetrix human array chip (Affymetrix Human
Genome U219 Strip, Santa Clara, CA, USA) at the IRB genomics facility. Affymetrix
raw CEL files have been deposited in the GEO database (GSE51895).
Microarray analysis. Expression data were analyzed using the R statistical
program. The RMA method was applied to the raw data. This comprises
three steps: convolution background adjustment, probe-level quantile normalization
and median polish summarization. Linear model analysis (LIMMA package,
Bioconductor) was used to identify the significant upregulated and downregulated
genes. A FDR multiple test was applied to the P-values obtained from the LIMMA
procedure; the upregulated and downregulated genes were considered to be
significant for the values of adjusted P≤ 0.05. Values of log2FC≥ 0.5 and
log2FC≤ 0.5, respectively, indicated the upregulated and downregulated genes.
Functional and pathway enrichment analysis. Functional annotation
of differentially expressed genes was based on GO (Consortium, 2000; http://www.
geneontology.org) as extracted from the EnsEMBL and the KEGG pathway
databases. Accordingly, all genes were classified into ontology categories. We took
only the GO/pathway categories that had at least 10 annotated genes. We used
GiTools for enrichment analysis and heatmap generation 37(www.gitools.org). The
resulting P-values were adjusted for multiple testing using Benjamin and Hochberg’s
FDR method.
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Putative TF motif occurrence in promoter region. The possible
occurrence of the TF motif in the promoter region (500-bp upstream and 200-bp
downstream of the transcription start site) was predicted with the STORM
algorithm,38 applying a cutoff of P= 0.0000125 and position frequency matrices
from the TRANSFAC database39 (professional version release 2009.4).
Statistical analyses. All data, except those from the arrays, were analyzed
using GraphPad Prism5 (GraphPad, San Diego, CA, USA). Student’s t-test and one-
or two-way ANOVA, incorporating Bonferroni multiple comparisons, were carried out
to evaluate the differences between the groups.
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